Zoetis Inc. $ZTS Shares Acquired by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Zoetis by 12.9% in Q4, buying 5,474,210 shares to own 47,780,974 shares (about 10.84%) worth roughly $6.01 billion.
• Zoetis beat Q4 estimates with $1.48 EPS and $2.39B revenue, set FY2026 guidance of 7.000–7.100 EPS, and announced a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield).

Vanguard Group Inc. lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 12.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,780,974 shares of the company's stock after buying an additional 5,474,210 shares during the quarter. Vanguard Group Inc. owned approximately 10.84% of Zoetis worth $6,011,802,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Summit Place Financial Advisors LLC increased its stake in Zoetis by 0.4% during the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company's stock worth $2,834,000 after purchasing an additional 76 shares during the period. CWA Asset Management Group LLC boosted its stake in shares of Zoetis by 1.1% in the third quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company's stock valued at $1,059,000 after purchasing an additional 80 shares during the period. YANKCOM Partnership boosted its stake in shares of Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company's stock valued at $302,000 after purchasing an additional 81 shares during the period. Evergreen Capital Management LLC grew its holdings in shares of Zoetis by 3.3% in the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company's stock valued at $394,000 after purchasing an additional 85 shares in the last quarter. Finally, Beese Fulmer Investment Management Inc. grew its holdings in shares of Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company's stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $116.92 on Monday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a fifty day moving average price of $120.83 and a 200 day moving average price of $125.28. The company has a market cap of $49.18 billion, a P/E ratio of 19.42, a PEG ratio of 1.78 and a beta of 0.98. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis's quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts predict that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is 35.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Piper Sandler reiterated a "neutral" rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Bank of America increased their price objective on Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a research note on Friday, February 13th. Finally, Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $152.25.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.